Figure 2.
Microparticles from patients with SLE increase HLA-DR and CD69 expression on monocytes. MFI of HLA-DR (a) and CD69 (b) on monocytes treated with or without 30 μg/mL of CMPs (MPs from controls) and SLE MPs (MPs from patients with SLE). Comparisons among groups were performed using the Kruskal–Wallis test; ∗p ≤ 0.05; ∗∗p ≤ 0.01. Results are shown as mean ± range, n = 7. The asterisks indicate statistically significant differences.